Figure 1.
Key milestones in the development of belimumab and the treatment of SLE and LN.
BLyS: B-lymphocyte stimulator; EMA: European Medicines Agency; FDA: Food and Drug Administration; GSK: GlaxoSmithKline; HGS: Human Genome Sciences; LN: lupus nephritis; SLE: systemic lupus erythematosus; ST: standard therapy for SLE; TIGR: The Institute for Genomics Research.